Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Neutral Land Securities Group (LAND) by JP Morgan
- Buy BT Group (BT.A) by Berenberg
- Sell Sage Group (SGE) by Canaccord Genuity
- Buy Secure Trust Bank (STB) by Berenberg
- Speculative Buy Hummingbird Resources (HUM) by Canaccord Genuity
- Hold M&G (MNG) by Berenberg
- Buy FD Technologies Public Limited Company (FDP) by Shore Capital
- Hold Land Securities Group (LAND) by Shore Capital
- Buy Tritax Big Box Reit (BBOX) by Shore Capital
- Buy Devolver Digital, Inc. (DI) Reg S Cat 3/144A (DEVO) by Shore Capital
- Watch Supermarket Income Reit (SUPR) by Jon Smith in The Motley Fool
- Buy Rolls-Royce Holdings (RR.) by Jon Smith in The Motley Fool
- Avoid Proteome Sciences (PRM) by Steve Moore in ShareProphets
- Buy Phoenix Group Holdings (PHNX) by Christopher Ruane in The Motley Fool
- Hold Britvic (BVIC) by Jefferies
- Watch Watches of Switzerland Group (WOSG) by Steve Moore in ShareProphets
- Watch Darktrace (DARK) by Gordon Best in The Motley Fool
- Buy Lloyds Banking Group (LLOY) by Harvey Jones in The Motley Fool
- Avoid Ilika (IKA) by Steve Moore in ShareProphets
- Buy Tullow Oil (TLW) by Bank of America
BiVictriX Therapeutics (BVX) Share Price
Health Care Sector
NOTE: This is based on 0 open tips for BiVictriX Therapeutics (BVX)
| Latest Bid : 11.00p | Latest Ask : 12.00p |
| High Today : 11.67p | Low Today : 11.50p |
| This Years High : 15.90p | This Years Low : 10.50p |
| Volume : 0 | MKT Cap : £9.84M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
BiVictriX Therapeutics (BVX) Overview
BVX has identified a unique, cancer-restricted antigen fingerprint, absent from healthy cells, which can be exploited to produce cancer selective therapeutics. The Bi-Cygni® technology has been developed to exploit this concept and expedite the development of bispecific therapeutics with an improved therapeutic index. Based on BVX's work to date, these ADCs demonstrate superior potency and tumour selectivity compared to conventional ADCs. The main country of operation is in the UK.BiVictriX Therapeutics (BVX) Active Short Positions
| Fund Manager | Position | Date | ||
|---|---|---|---|---|
| No active short positions | ||||
| Latest Bid : 11.00p | Latest Ask : 12.00p |
| High Today : 11.67p | Low Today : 11.50p |
| This Years High : 15.90p | This Years Low : 10.50p |
| Volume : 0 | MKT Cap : £9.84M |
BiVictriX Therapeutics Overview
BVX has identified a unique, cancer-restricted antigen fingerprint, absent from healthy cells, which can be exploited to produce cancer selective therapeutics. The Bi-Cygni® technology has been developed to exploit this concept and expedite the development of bispecific therapeutics with an improved therapeutic index. Based on BVX's work to date, these ADCs demonstrate superior potency and tumour selectivity compared to conventional ADCs. The main country of operation is in the UK.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.